Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

Cai -FAVIPIRAVIR, 2020
 
ChiCTR2000029600
NRainterferoninterferonCOVID 19 all comersNA
35/45 suggested
  • suggested 5.5-fold increase in clinical improvement,clinical improvement (14-day)

COVID-19 mild to moderate meta-analysis

Idelsis, 2020
 
RPCEC00000307
RCTinterferoninterferonCOVID-19 mild to moderatehigh
30/33 conclusif
  • demonstrated 2.3-fold increase in PCR-negative conversion (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).